Nektar Therapeutics (NKTR) — Cash Flow Reinvestment Rate
Nektar Therapeutics (NKTR) has a Cash Flow Reinvestment Rate of 0.93x as of June 2018, reinvesting $897.05 Million (capex $2.75 Million plus investments $-894.30 Million) from operating cash flow of $959.64 Million. Check NKTR operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Nektar Therapeutics Cash Flow Reinvestment Rate (1997–2018)
Historical reinvestment intensity for Nektar Therapeutics across 4 annual periods. Explore NKTR long-term investment intensity to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Nektar Therapeutics (1997–2018)
Year-by-year capital reinvestment analysis for Nektar Therapeutics. For live market cap and broader valuation context, see market value of Nektar Therapeutics.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2018 | 1.93x | $1.38 Billion | $718.21 Million | $14.24 Million | ▲ +269.5% |
| 2009 | 0.52x | $20.70 Million | $39.74 Million | $20.70 Million | ▲ +132.4% |
| 2007 | 0.22x | $32.80 Million | $146.30 Million | $32.80 Million | ▼ -93.5% |
| 1997 | 3.47x | $17.26 Million | $4.98 Million | $17.26 Million | — |